Department of Internal Medicine, Sultan 2.Abdülhamid Han Training and Research Hospital, University of Health Sciences, İstanbul, Turkey.
Department of Gastroenterology, Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, University of Health Sciences, İstanbul, Turkey.
Turk J Med Sci. 2022 Dec;52(6):1821-1828. doi: 10.55730/1300-0144.5528. Epub 2022 Dec 21.
Acute pancreatitis is a clinical picture with a wide range of symptoms from mild inflammation to multiorgan failure and death. The aim of this study is to investigate the effects of Adalimumab (ADA) on inflammation and apoptosis in a cerulein-induced acute pancreatitis model in rats.
Experimental cerulein-induced acute pancreatitis model was created by applying 4 intraperitoneal cerulein injections at 1-h intervals. A total of 40 rats, 8 in each group, were randomly distributed into five groups. In the groups that ADA treatment was given, two different doses of ADA were administered 5 mg/kg and 20 mg/kg as low and high doses, respectively. The rats were sacrificed 12 h after the last intraperitoneal administration of ADA. Blood samples were obtained from each rat for amylase, IL-6, and IL-1β measurements. Hematoxylin and Eosin (H&E) stains were used to undertake the histopathological analysis of the pancreas. The terminal deoxynucleotidyl transferase-mediated nick-end-labeling (TUNEL) method was used to evaluate apoptosis.
: Plasma amylase, IL-6, and IL-1β levels were significantly elevated in acute pancreatitis groups (p < 0.05). It was determined that both low (5 mg/kg) and high doses (20 mg/kg) of ADA ameliorated the parameters (plasma amylase, IL-6, and IL-1β) (p < 0.05). Although significant improvements were detected in the Schoenberg scoring system and the apoptotic index from the TUNEL method after highdose ADA treatment, no significant amelioration was observed in the histopathological examinations in the low-dose ADA group.
: It has been determined that the administration of high-dose ADA effectively alleviated the symptoms of acute pancreatitis and reduced the level of apoptosis. In line with the findings of our study, we have predicted that high-dose (20 mg/kg) ADA can be used as an effective and safe drug in the treatment of patients with acute pancreatitis.
急性胰腺炎是一种临床表现，其症状从轻度炎症到多器官衰竭和死亡范围广泛。本研究旨在探讨阿达木单抗（ADA）对大鼠雨蛙肽诱导的急性胰腺炎模型中炎症和细胞凋亡的影响。
通过每 1 小时腹腔内注射 4 次雨蛙肽，创建实验性雨蛙肽诱导的急性胰腺炎模型。总共 40 只大鼠，每组 8 只，随机分为 5 组。在给予 ADA 治疗的组中，给予两种不同剂量的 ADA，分别为低剂量 5mg/kg 和高剂量 20mg/kg。在最后一次腹腔内给予 ADA 后 12 小时处死大鼠。从每只大鼠中采集血液样本，用于测量淀粉酶、IL-6 和 IL-1β。使用苏木精和伊红（H&E）染色对胰腺进行组织病理学分析。使用末端脱氧核苷酸转移酶介导的缺口末端标记（TUNEL）法评估细胞凋亡。
急性胰腺炎组的血浆淀粉酶、IL-6 和 IL-1β水平显著升高（p<0.05）。发现低剂量（5mg/kg）和高剂量（20mg/kg）ADA 均可改善这些参数（血浆淀粉酶、IL-6 和 IL-1β）（p<0.05）。尽管高剂量 ADA 治疗后 Schoenberg 评分系统和 TUNEL 法的凋亡指数有显著改善，但在低剂量 ADA 组的组织病理学检查中未观察到明显改善。
已确定高剂量 ADA 的给药可有效缓解急性胰腺炎的症状并降低细胞凋亡水平。与我们的研究结果一致，我们预测高剂量（20mg/kg）ADA 可作为治疗急性胰腺炎患者的有效且安全的药物。
